Companies · Other Health Care

InspireMD, Inc.

MIAMI · Other Health Care

Diligence memoA one-page analyst read on InspireMD, Inc. — recommendation, valuation, rhythm, risks.
$117.2M
Total raised · real
15
Rounds
1.0×
Latest step-up
Top 4%
Sector rank · raised
Series C
Latest stage · inferred · Wed Jul 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

InspireMD, Inc. looks fair against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.10× the median modeled value of Series C Other Health Care companies in 2025–2027 (20 peers) — value vs value, same stage and era.
  • Within the normal band (110% of peer median) for its niche.
Active
  • Last raise 11 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

InspireMD, Inc. is one of 5376 Other Health Care companies tracked from MIAMI. By capital raised it ranks among the largest (ahead of 97% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
18
Investors (latest)
2025-07-30
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2011-03-31 Raised $6.5M (real) Modeled valuation $132M (est)Series A2011Series A · 2011-03-31 Raised $8.0M (real) Modeled valuation $162M (est)Series A2011Seed · 2011-03-31 Raised $1.5M (real) Modeled valuation $37M (est)Seed2011Pre-Seed · 2011-03-31 Raised $212K (real) Modeled valuation $6.5M (est)Pre-Seed2011Series A · 2011-04-18 Raised $425K (real) Modeled valuation $8.6M (est)Series A2011Series A · 2012-04-05 Raised $11M (real) Modeled valuation $222M (est)Series A2012Series A · 2012-09-14 Raised $409K (real) Modeled valuation $8.2M (est)Series A2012Series A · 2012-09-27 Raised $450K (real) Modeled valuation $9.1M (est)Series A2012Series A · 2012-10-24 Raised $1.8M (real) Modeled valuation $36M (est)Series A2012Series A · 2013-01-03 Raised $3.1M (real) Modeled valuation $62M (est)Series A2013Series A · 2016-03-21 Raised $610K (real) Modeled valuation $12M (est)Series A2016Series A · 2016-06-13 Raised $182K (real) Modeled valuation $3.7M (est)Series A2016Series A · 2017-12-01 Raised $750K (real) Modeled valuation $15M (est)Series A2017Series C · 2023-05-12 Raised $42M (real) Modeled valuation $462M (est)Series C2023Series C · 2025-07-30 Raised $40M (real) Modeled valuation $248M (est)Series C2025Cumulative $117M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$6.5M · 2011
Series A extension$8.0M · 2011
Bridge · Series A-stage$1.5M · 2011smaller follow-on
Bridge · Series A-stage$212K · 2011smaller follow-on
Series A extension$425K · 2011
Series A extension$11.0M · 2012
Series A extension$409K · 2012
Series A extension$450K · 2012
Series A extension$1.8M · 2012
Series A extension$3.1M · 2013
Series A extension$610K · 2016
Series A extension$182K · 2016
Series A extension$750K · 2017
Series C$42.2M · 2023no Series B on file
Series C extension$40.1M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 80%.

Modeled valuation trajectory
$248.1M
Base estimate est.
$145.6M
Conservative case
$324.9M
Upside case
$267.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series A · modeled $131.7M · 2011-03-312011Series A · modeled $162.3M · 2011-03-31Seed · modeled $37.2M · 2011-03-31Pre-Seed · modeled $6.5M · 2011-03-31Series A · modeled $8.6M · 2011-04-18Series A · modeled $222.0M · 2012-04-05Series A · modeled $8.2M · 2012-09-14Series A · modeled $9.1M · 2012-09-27Series A · modeled $35.6M · 2012-10-24Series A · modeled $62.4M · 2013-01-03Series A · modeled $12.3M · 2016-03-21Series A · modeled $3.7M · 2016-06-13Series A · modeled $15.1M · 2017-12-01Series C · modeled $461.8M · 2023-05-12Series C · modeled $248.1M · 2025-07-302025
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
73%
Survival probability
55% low · 85% high
1.29×/yr
Annual markup
1.48×/yr upside case
0.9 yr
Elapsed time used
0.9 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
12 mo
Avg between rounds
$8.2M/yr
Capital velocity
15.3 yr
On record since
2011
First round
15
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 48× above median
This company$117.2M
Sector median$2.4M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.9× of median
This company$40.1M
Sector median$45.9M
Modeled value — vs sector median (estimate, all stages) 11× above median
This company$248.1M
Sector median$22.1M

Raised more than 97% of sector peers (real $). Modeled value above 89% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #9 of 20.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)RESTOR3D, Inc. · Series C Raised $239.2M · modeled $522.0M (est)ByHeart, Inc. · Series C Raised $378.4M · modeled $493.2M (est)SpyGlassPharma, Inc. · Series C Raised $134.8M · modeled $484.8M (est)VantAI Holdings, Inc. · Series C Raised $86.3M · modeled $475.3M (est)BioIntelliSense, Inc. · Series C Raised $140.0M · modeled $328.7M (est)ObjectiveHealth, Inc. · Series C Raised $68.0M · modeled $321.0M (est)VentureMed Group, Inc. · Series C Raised $59.8M · modeled $288.0M (est)Exo Imaging, Inc. · Series C Raised $169.6M · modeled $284.4M (est)Fonar, Llc · Series C Raised $51.2M · modeled $228.9M (est)MicroTransponder, Inc. · Series C Raised $117.7M · modeled $223.2M (est)Fourth Edge LLC · Series C Raised $119.7M · modeled $221.8M (est)InspireMD, Inc. (this company) Raised $117.2M · modeled $248.1M (est)InspireMD, Inc.
CompanyStageRaised · realValue · estvs peer med.
RESTOR3D, Inc.Series C$239.2M$522.0M2.31×
ByHeart, Inc.Series C$378.4M$493.2M2.18×
SpyGlassPharma, Inc.Series C$134.8M$484.8M2.14×
VantAI Holdings, Inc.Series C$86.3M$475.3M2.10×
BioIntelliSense, Inc.Series C$140.0M$328.7M1.45×
ObjectiveHealth, Inc.Series C$68.0M$321.0M1.42×
VentureMed Group, Inc.Series C$59.8M$288.0M1.27×
Exo Imaging, Inc.Series C$169.6M$284.4M1.26×
InspireMD, Inc. this companySeries C$117.2M$248.1M1.10×
Fonar, LlcSeries C$51.2M$228.9M1.01×
MicroTransponder, Inc.Series C$117.7M$223.2M0.99×
Fourth Edge LLCSeries C$119.7M$221.8M0.98×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$6.5M2011-03-31$29.7M$131.7M85%
Series A$8.0M2011-03-31$36.5M$162.3M85%
Seed$1.5M2011-03-31$7.5M$37.2M85%
Pre-Seed$212K2011-03-31$1.2M$6.5M85%
Series A$425K2011-04-18$1.9M$8.6M85%
Series A$11.0M2012-04-05$50.0M$222.0M85%
Series A$409K2012-09-14$1.9M$8.2M85%
Series A$450K2012-09-27$2.0M$9.1M85%
Series A$1.8M2012-10-24$8.0M$35.6M85%
Series A$3.1M2013-01-03$14.0M$62.4M85%
Series A$610K2016-03-21$2.8M$12.3M85%
Series A$182K2016-06-13$829K$3.7M85%
Series A$750K2017-12-01$3.4M$15.1M90%
Series C$42.2M2023-05-12$281.1M$461.8M90%
Series C$40.1M2025-07-30$267.1M$248.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$6.5M2011-03-31
    • First recorded raise — entered as Series A.
    • 16 investors on this round.
  2. Series A$8.0M2011-03-31
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 24 investors on this round.
  3. Seed$1.5M2011-03-31
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 5.4× smaller than the prior — bridge or down round.
    • 3 investors on this round.
  4. Pre-Seed$212K2011-03-31
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 7.1× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  5. Series A$425K2011-04-18
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
    • 2 investors on this round.
  6. Series A$11.0M2012-04-05
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 25.9× larger than the prior — scaling up.
    • 6 investors on this round.
  7. Series A$409K2012-09-14
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 26.9× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  8. Series A$450K2012-09-27
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  9. Series A$1.8M2012-10-24
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 3.9× larger than the prior — scaling up.
    • 1 investor on this round.
  10. Series A$3.1M2013-01-03
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 1.8× larger than the prior — scaling up.
    • 1 investor on this round.
  11. Series A$610K2016-03-21
    • Raised again after 39 mo — slower than the ~14 mo sector norm.
    • Round 5.1× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 4 investors on this round.
  12. Series A$182K2016-06-13
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round 3.3× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  13. Series A$750K2017-12-01
    • Raised 18 mo later, in step with the ~14 mo sector norm.
    • Round 4.1× larger than the prior — scaling up.
    • 1 investor on this round.
  14. Series C$42.2M2023-05-12
    • Raised again after 65 mo — slower than the ~14 mo sector norm.
    • Round 56.2× larger than the prior — scaling up.
    • 18 investors on this round.
  15. Series C$40.1M2025-07-30
    • Raised again after 27 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 18 investors on this round.
Intelligence
2026 ~Q3
Modeled next raise · ~12mo cadence
$40.1M
Modeled next size est.range $40.1M$64.1M
1.0×
Last step-up
$8.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Isaac Blech13 other2016-03
Michael Berman6 other2016-03
Sol Barer5 other2012-04
Sol J. Barer5 other2011-03
James Barry4 other2012-04
Asher Holzer3 other2011-03
Eli Bar2 other2012-09
Alan Milinazzo1 other2016-03
Eyal Weinstein1 other2012-04
James J. Barry1 other2012-09
James J. Loughlin1 other2012-09
Ofir Paz1 other2011-03
Paul Stuka1 other2012-04
Scott R. Ward1 other2025-07
Alan W. Milinazzo2013-01
Andrea Tommasoli2023-05
Asher J. Holzer2012-09
Campbell Rogers2016-03
Craig Shore2011-03
Craig W. Shore2013-01
Eli W. Bar2013-01
Eyal J Weinstein2011-03
Gary J. Roubin, M.D.2023-05
James Loughlin2016-03
Registry & provenance

InspireMD, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1433607
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Edge Therapeutics, Inc.PharmaceuticalsSeries C$72.1M$2.0Bnetwork3 shared operators · same stage
Centrexion Therapeutics CorpBiotechnologySeries C$202.0M$35.2Mnetwork3 shared operators · same stage
InspireMD Ltd.BiotechnologySeed$1.6M$70.2Mnetwork4 shared operators
Diffusion Pharmaceuticals Inc.PharmaceuticalsSeries C$140.0M$26.3Mnetwork2 shared operators · same stage
Neotract IncOther Health CareSeries C$117.5M$293.0Msame sector · same stage
MicroTransponder, Inc.Other Health CareSeries C$117.7M$223.2Msame sector · same stage
Calyxo, Inc.Other Health CareSeries C$115.9M$204.7Msame sector · same stage
Fourth Edge LLCOther Health CareSeries C$119.7M$221.8Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Inspire Veterinary Partners, Inc.Other Health CareSeries A$1.1M89%
Inspire Medical Systems, Inc.HealthtechSeries B$309.8M88%
THINKmd, Inc.Other Health CareSeries A$50.2M86%
EvolvedMD, Inc.Other Health CareSeries B$139.0M86%
AngelMD, Inc.Other Health CareSeries A$245.0M85%
AdvocateMH Inc.Other Health CareSeries A$23.8M84%
ImageMoverMD, Inc.Other Health CareSeed$39.7M84%
Inspired Biometrics Inc.Other Health CarePre-Seed$3.6M83%
Frequently asked
How much funding has InspireMD, Inc. raised?
InspireMD, Inc. has raised approximately $117.2M in disclosed capital across 15 recorded financing rounds, aggregated from public filings.
What is InspireMD, Inc.'s estimated valuation?
Provath's modeled valuation for InspireMD, Inc. is approximately $248.1M (modeled range $145.6M–$324.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is InspireMD, Inc. at?
InspireMD, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Wed Jul 30.
What does InspireMD, Inc. do and where is it based?
InspireMD, Inc. operates in the Other Health Care sector, based in MIAMI.
Explore related

See where InspireMD, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at InspireMD, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.